133 related articles for article (PubMed ID: 23025719)
21. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
Mikami S; Nakamura S; Ashizawa T; Nomura I; Kawasaki M; Sasaki S; Oki H; Kokubo H; Hoffman ID; Zou H; Uchiyama N; Nakashima K; Kamiguchi N; Imada H; Suzuki N; Iwashita H; Taniguchi T
J Med Chem; 2017 Sep; 60(18):7677-7702. PubMed ID: 28796496
[TBL] [Abstract][Full Text] [Related]
22. Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor.
Krier M; Araújo-Júnior JX; Schmitt M; Duranton J; Justiano-Basaran H; Lugnier C; Bourguignon JJ; Rognan D
J Med Chem; 2005 Jun; 48(11):3816-22. PubMed ID: 15916433
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
[TBL] [Abstract][Full Text] [Related]
24. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
25. New orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
[TBL] [Abstract][Full Text] [Related]
26. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U
J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629
[TBL] [Abstract][Full Text] [Related]
27. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.
Guo C; McAlpine I; Zhang J; Knighton DD; Kephart S; Johnson MC; Li H; Bouzida D; Yang A; Dong L; Marakovits J; Tikhe J; Richardson P; Guo LC; Kania R; Edwards MP; Kraynov E; Christensen J; Piraino J; Lee J; Dagostino E; Del-Carmen C; Deng YL; Smeal T; Murray BW
J Med Chem; 2012 May; 55(10):4728-39. PubMed ID: 22554206
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.
Su T; Zhang T; Xie S; Yan J; Wu Y; Li X; Huang L; Luo HB
Sci Rep; 2016 Feb; 6():21826. PubMed ID: 26911795
[TBL] [Abstract][Full Text] [Related]
29. Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.
Malosh C; Turlington M; Bridges TM; Rook JM; Noetzel MJ; Vinson PN; Steckler T; Lavreysen H; Mackie C; Bartolomé-Nebreda JM; Conde-Ceide S; Martínez-Viturro CM; Piedrafita M; Sánchez-Casado MR; Macdonald GJ; Daniels JS; Jones CK; Niswender CM; Conn PJ; Lindsley CW; Stauffer SR
Bioorg Med Chem Lett; 2015 Nov; 25(22):5115-20. PubMed ID: 26475522
[TBL] [Abstract][Full Text] [Related]
30. 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
Soth M; Abbot S; Abubakari A; Arora N; Arzeno H; Billedeau R; Dewdney N; Durkin K; Frauchiger S; Ghate M; Goldstein DM; Hill RJ; Kuglstatter A; Li F; Loe B; McCaleb K; McIntosh J; Papp E; Park J; Stahl M; Sung ML; Suttman R; Swinney DC; Weller P; Wong B; Zecic H; Gabriel T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3452-6. PubMed ID: 21515047
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
Kim I; Song JH; Park CM; Jeong JW; Kim HR; Ha JR; No Z; Hyun YL; Cho YS; Sook Kang N; Jeon DJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):922-6. PubMed ID: 20053559
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
33. Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor.
Nagy D; Tingley FD; Stoiljkovic M; Hajós M
Exp Neurol; 2015 Jan; 263():122-31. PubMed ID: 25315303
[TBL] [Abstract][Full Text] [Related]
34. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
Ducray R; Ballard P; Barlaam BC; Hickinson MD; Kettle JG; Ogilvie DJ; Trigwell CB
Bioorg Med Chem Lett; 2008 Feb; 18(3):959-62. PubMed ID: 18182285
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
Altenbach RJ; Liu H; Banfor PN; Browman KE; Fox GB; Fryer RM; Komater VA; Krueger KM; Marsh K; Miller TR; Pan JB; Pan L; Sun M; Thiffault C; Wetter J; Zhao C; Zhou D; Esbenshade TA; Hancock AA; Cowart MD
J Med Chem; 2007 Nov; 50(22):5439-48. PubMed ID: 17918921
[TBL] [Abstract][Full Text] [Related]
36. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task.
Vardigan JD; Converso A; Hutson PH; Uslaner JM
J Neurogenet; 2011 Dec; 25(4):120-6. PubMed ID: 22070409
[TBL] [Abstract][Full Text] [Related]
37. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
[TBL] [Abstract][Full Text] [Related]
38. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
[TBL] [Abstract][Full Text] [Related]
39. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
[TBL] [Abstract][Full Text] [Related]
40. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
